CFM
XFOR icon

Catalyst Funds Management’s X4 Pharmaceuticals XFOR Stock Holding History

Catalyst Funds Management’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-47,383
Closed -$196K – 911
2026
Q1 		$196K Buy
+47,383
New +$177K 0.03% 461

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Catalyst Funds Management's XFOR Position: Q2 2026 in Review

Catalyst Funds Management sold out of X4 Pharmaceuticals (XFOR) in Q2 2026, closing a stake of 47,383 shares — an estimated $196K sold.

Catalyst Funds Management first reported a position in XFOR in Q1 2026 and held it in 1 quarter. The position peaked at $196K in Q1 2026. 89 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

  • Catalyst Funds Management reported no remaining X4 Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Catalyst Funds Management sold 47,383 X4 Pharmaceuticals shares in Q2 2026, an estimated $196K.
  • Catalyst Funds Management first reported a position in X4 Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Catalyst Funds Management's X4 Pharmaceuticals position peaked at $196K in Q1 2026.
  • 89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.